Iconovo (ICO) Q4 2025 earnings summary

Executive summary

• Focus shifted to accelerating partnerships and increasing self-financing through upfront and milestone payments, aiming for cash flow from sales and royalties by 2029.

• Leadership transition with Anders Månsson appointed as interim CEO; permanent recruitment process underway.

• Business model targets both novel and generic pharmaceuticals, leveraging five proprietary inhaler platforms.

Financial highlights

• Net sales for Q4 2025 were TSEK 504, down from TSEK 986 in Q4 2024; full-year 2025 net sales were TSEK 1,105, down from TSEK 2,934 in 2024.

• Operating loss for Q4 2025 was TSEK -12,940 (Q4 2024: -10,763); full-year operating loss was TSEK -43,113 (2024: -41,076).

• Cash and cash equivalents at year-end were TSEK 6,560, with an additional SEK 25 million received from a share issue in January 2026.

• Earnings per share for Q4 2025 were SEK -0.24 (Q4 2024: -0.59); full-year 2025 EPS was SEK -1.14 (2024: -2.57).

Outlook and guidance

• Previous financial targets withdrawn; new targets to focus on value optimization and commercialization, especially for the GLP-1 analogue semaglutide project.

• Share issues in late 2025 and early 2026 secure operations for at least 12 months, supporting ongoing licensing efforts.